An International Expanded Access Program (EAP) of RAD001 (everolimus) in patients with metastatic renal cell carcinoma (mRCC) who fail, or become intolerant of a prior vascular endothelial growth factor receptor (VEGFr) therapy

Grünwald, V., Rah, S. Y., Miller, K., Karakiewicz, P. I., Machiels, J.-P., Hajdenberg, J. J., Rini, B. I., Rosamilia, M., Resta, D., & Lee, S. H. (2009). An International Expanded Access Program (EAP) of RAD001 (everolimus) in patients with metastatic renal cell carcinoma (mRCC) who fail, or become intolerant of a prior vascular endothelial growth factor receptor (VEGFr) therapy. EJC - Supplements, 7(2), 440. https://hdl.handle.net/2078.5/147006 (Original work published 2009)